capecitabine / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

94 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
Ni-HIGH, UMIN000034222: A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer

Active, not recruiting
1b
45
Japan
Opdivo (nivolumab) - Ono Pharma, BMS, capecitabine - Generic mfg., oxaliplatin - Generic mfg., Herceptin (trastuzumab) - Roche
The Cancer Institute Hospital of JFCR, Ono Pharmaceutical Co., Ltd.
HER2 positive advanced or unresectable gastric cancer
 
 
CORINTH, NCT04046133: Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

Recruiting
1b
50
Europe
Pembrolizumab, Radiotherapy, Chemotherapy (Mytomycin or Mitomycin and Capecitabine)
Cardiff University
Anal Cancer Stage III A, Anal Cancer Stage III B
11/22
11/22
CRIMI, NCT03844256 / 2017-004751-23: A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the Study

Recruiting
1b
50
Europe
nivolumab 480mg, mitomycin-c 12mg/m2 IV, capecitabine 750mg/m2, radiotherapy 40Gy in 20 fractions of 2Gy, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Bristol-Myers Squibb
Urinary Bladder Cancer, Invasive Bladder Cancer
07/24
07/26
ACTRN12620001317987: A study to assess if pantoprazole affects the absorption of capecitabine in patients with breast and gastrointestinal cancers.

Not yet recruiting
1
20
 
Auckland District Health Board, Gut Cancer Foundation New Zealand
Breast Cancer, Gastrointestinal Cancer, colorectal cancer
 
 
ACTRN12623001072606: A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Not yet recruiting
1
45
 
South Metropolitan Health Service (SMHS), Fiona Stanley Hospital
metastatic castration-resistant prostate cancer
 
 
2015-003965-27: Finding the optimal dose of a new drug M6620 in combination with chemoradiotherapy for the treatment of oesophageal cancer & other cancer

Not yet recruiting
1
65
Europe
M6620, Cisplatin, Capecitabine, M6620, Solution for infusion, Tablet
University of Oxford, Cancer Research UK, University of Oxford, Merck kGaA, Darmstadt Germany
Stage A1 and B: Oesophageal carcinomaStage A2: Any advanced solid tumours (carcinomas), Cancer of the oesophagous (all stages) and other cancers which cannot be operated on and have spread to other parts of the body (stage A2 only)., Diseases [C] - Cancer [C04]
 
 
ChiCTR-TRC-08000160: Clinical research of capecitabine in the adjuvant chemotherapy of postoperative liver cancer

Completed
1
60
 
Regular postoperative therapy is the same as the control group. Intake of capecitabine: 1000mg/m2, Bid, oral intake in 30 minutes after meals. ;Regular postoperative therapy includes medicines for liver supporting and preventive interventional treatment and immunotherapy.
Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University; Level of the institution：, Self-financing
Primary liver cancer after surgery
 
 
ChiCTR-TNC-07000014: Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer

Completed
1
200
 
Capecitabine plus paclitaxel with sequential capecitabine alone
School of Oncology, Peking University; Level of the institution：, American Roche Company, Ltd., the Project in Support of the State 863 Program
Advanced gastric cancer
 
 
ChiCTR-TNC-10000787: Feasibility study of postoperative concurrent radiotherapy and chemotherapy for locally advanced gastric cancer patients

Completed
1
15
 
From the first day of radiotherapy, Capecitabine was administered 600 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total. ;From the first day of radiotherapy, Capecitabine was administered 700 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total. ;From the first day of radiotherapy, Capecitabine was administered 800 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total. ;From the first day of radiotherapy, Capecitabine was administered 850 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total. ;From the first day of radiotherapy, Capecitabine was administered 900 mg/m2 twice a day (b.i.d.) orally (PO), d1–14, every 21 days, 2 cycles in total.
Peking University School of Oncology, Beijing Cancer Hospital & Institute; Level of the institution：, Beijing Cancer Hospital Fund
Locally Advanced Gastric Cancer
 
 
ChiCTR-ONRC-13004023: Phase I Clinical Trial of 7-Day Capecitabine in Combination with Docetaxel and Oxaliplatin in the Treatment of Advanced Malignant Solid Tumors

Completed
1
12
 
docetaxel 75 mg/m2, d1; q21d+oxaliplatin100mg/m2, d1; q21d+capecitabine1000mg/m2, bid, d1-7; q21d ;docetaxel 75 mg/m2, d1; q21d+oxaliplatin120mg/m2, d1; q21d+capecitabine1000mg/m2, bid, d1-7; q21d ;docetaxel 75 mg/m2, d1; q21doxaliplatin100mg/m2, d1; q21d+oxaliplatin100mg/m2, d1; q21d+capecitabine1250mg/m2, bid, d1-7; q21d
Affiliated Cancer Hospital of Guangxi Medical University/Cancer Hospital of Guangxi Zhuang Autonomous Region; Affiliated Cancer Hospital of Guangxi Medical University, Guangxi nature science fund; Guangxi health care key scientific research project; Guangxi self-financing scientific research project
Advanced malignant solid tumor
 
 
ChiCTR-TRC-08000122: Randomized controlled study on preoperative chemoradiation assisted radical operation for mid-low rectal carcinoma

Recruiting
1
400
 
1. Routine preoperative radiotherapy (2 Gy once a day, 5 times/ week, for total 46 Gy) + concurrent chemotherapy (mXelox) + total mesorectum excision; 2. Postoperative chemotherapy: Xelox. ;Total mesorectum excision; postoperative chemotherapy: Xelox
Sun Yat-sen University; Level of the institution：, Clinical Trials Program of Sun Yat-sen University (“5010” Program)
Rectal carcinoma
 
 
NCT02009449: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Checkmark In combination with pembrolizumab/ nivolumab for advanced RCC
Sep 2019 - Sep 2019: In combination with pembrolizumab/ nivolumab for advanced RCC
Checkmark Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Checkmark From AM0010/AM0010 + anti-PD-1 in NSCLC at ESMO 2017 [screenshot]
More
Active, not recruiting
1
350
US
Pegilodecakin, LY3500518, AM0010, PEGylated recombinant human Interleukin-10, PEG-rHuIL-10, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, Taxol or taxotere and paraplatin or platinol, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), Eloxatin®/Leucovorin/5-FU, gemcitabine/nab-paclitaxel, Gemzar/Abraxane ABI-007, Capecitabine, Xeloda, Pazopanib, GW786034, Pembrolizumab, Keytruda, MK-3475, Paclitaxel, nivolumab, Keytruda, Gemcitabine/carboplatin, gemzar/paraplatin
Eli Lilly and Company, ARMO BioSciences
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
02/19
08/24
NCT05888675: Clinical Study of Weifuchun Treatment on Gastric Cancer

Completed
1
72
NA
Weifuchun
ShuGuang Hospital
Gastric Cancer (Diagnosis)
10/20
10/20
ChiCTR1900021580: Docetaxel and capecitabine chemotherapy combined with local radiotherapy for initial unresectable locally advanced gastric cancer or para-aortic lymph node metastatic gastric cancer stage I clinical study

Not yet recruiting
1
18
 
Docetaxel + capecitabine
Sichuan Provincial Tumor Hospital; Sichuan Provincial Tumor Hospital, At his own expense
gastric carcinoma
 
 
NCT06547385: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Active, not recruiting
1
40
Japan
ONO-4578, ONO-4538, Nivolumab, Capecitabine, XELODA, Oxaliplatin, ELPLAT, Fluorouracil, 5-FU, Calcium Levofolinate Hydrateb, ISOVORIN, Bevacizumab, AVASTIN
Ono Pharmaceutical Co. Ltd
Colorectal Cancer
10/27
10/27
NCT02435927: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

Checkmark Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Jan 2019 - Jan 2019: Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Active, not recruiting
1
60
RoW
ASLAN001+ CAPOX (Oxaliplatin, capecitabine), eloxatin, xeloda, ASLAN001 + mFolfox6 (5-FU, leucovorin), 5-Fluorouracil, Folinic acid
National Cancer Centre, Singapore, Aslan Pharmaceuticals, National Medical Research Council (NMRC), Singapore
Solid Tumors
06/21
06/21
GEP14-LEECAP, NCT02754011: Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative

Completed
1
18
Europe
Combination of ribociclib + capecitabine, Combination of LEE011 and XELODA
UNICANCER, Novartis
Breast Cancer
02/22
12/22
NCT03300544: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated
1
3
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
03/22
03/22
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Not yet recruiting
1
60
NA
SCT-I10A, SCT200, Chemotherapy
Sinocelltech Ltd.
Esophageal Squamous Cell Carcinoma, Colorectal Cancer
08/22
12/22
McCrest-2, NCT04510818: Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Recruiting
1
20
RoW
Capecitabine, Camrelizumab
Ruijin Hospital
Head and Neck Cancer, Esophageal Squamous Cancer
08/22
08/24
NCT04508686: Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Recruiting
1
20
RoW
Capecitabine, camrelizumab
Ruijin Hospital
Advanced Cervical Cancer
08/22
08/24
NCT05908838: Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer

Completed
1
146
NA
Modified Banxia Xiexin Decoction, combination chemotherapy with Placebo granules
ShuGuang Hospital
Gastric Cancer (Diagnosis)
12/22
12/22
NCT04608786: A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Enrolling by invitation
1
10
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, Capecitabine
Lee's Pharmaceutical Limited
Biliary Tract Cancer
12/22
12/23
NCT04850235: Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Active, not recruiting
1
36
RoW
Nab paclitaxel
Sun Yat-sen University
Nasopharyngeal Cancer
12/22
12/24
ChiCTR2100042988: A single-arm, open phase Ib clinical study of ZKAB001 combined with capecitabine for adjuvant treatment of patients with malignant tumors of the biliary system

Recruiting
1
10
 
Regiments
Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University; Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Guangzhou Zhaoke Pharmaceutical Co., Ltd.
Malignant tumor of biliary system
 
 
CEDAR, NCT03916510: Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer

Completed
1
13
Europe
Enadenotucirev, Capecitabine, Radiotherapy
University of Oxford, Akamis Bio, Cancer Research UK
Locally Advanced Rectal Cancer
02/23
02/23
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Recruiting
1
18
RoW
Lenvatinib
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Gastric Carcinoma
03/23
10/23
NCT05315830: A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Recruiting
1
10
RoW
HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
First Affiliated Hospital Bengbu Medical College
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
03/23
03/24
GEN-602-CT-101, NCT03775525: Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Active, not recruiting
1
127
US
GZ17-6.02, Capecitabine, Xeloda
Genzada Pharmaceuticals USA, Inc., Translational Drug Development
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
05/23
12/23
NCT03958721: Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Completed
1
20
US
Capecitabine, Radiotherapy
A Bapsi Chakravarthy, MD
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
10/23
10/23
McCrest-3, NCT04932187: Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Recruiting
1
20
RoW
Capecitabine, Camrelizumab
Ruijin Hospital
Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
07/23
07/25
NCT04802980: A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

Recruiting
1
72
RoW
HB002.1T, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin
Huabo Biopharm Co., Ltd.
Solid Tumor
07/23
09/23
NCT04400383: Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Completed
1
62
RoW
AB011 Injection, recombinant humanized anti-Claudin 18.2 monoclonal antibody injection, recombinant humanized anti-CLDN 18.2 monoclonal antibody injection
CARsgen Therapeutics Co., Ltd., Shanghai East Hospital
Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
07/23
09/23
DESTINY-Breast08, NCT04556773: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer
Checkmark Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Jun 2022 - Jun 2022: Initial efficacy/safety data from DESTINY-Breast08 trial for HER2-low metastatic breast cancer at ASCO 2022
Active, not recruiting
1
138
Europe, Canada, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Durvalumab, MEDI4736, Paclitaxel, Taxol A, Capivasertib, AZD5363, Anastrozole, Anastrozol, Fulvestrant, Capecitabine
AstraZeneca, Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
Metastatic Breast Cancer
08/23
11/25
NCT05774886: Implantable Microdevice for TNBC - Pilot Study

Withdrawn
1
24
NA
Implantable Microdevice (IMD)
Dana-Farber Cancer Institute
Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer, Early Stage Triple-Negative Breast Carcinoma, Breast Neoplasms, Breast Carcinoma
09/23
09/28
NCT02669173: Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Active, not recruiting
1
12
US
Capecitabine, Bevacizumab
Case Comprehensive Cancer Center
Glioblastoma
03/19
11/24
NCT04429321: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Terminated
1
1
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, bland embolization, trans-arterial embolization
Abramson Cancer Center at Penn Medicine
Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV
01/24
01/24
PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting
1
200
Europe, Japan, US, RoW
M9140, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Colorectal Cancer
02/26
02/26
NCT04487236: Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
84
RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle, ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
12/23
06/24
NCT04920032: Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting
1
22
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11, Standard Treatment, Signatera MRD ctDNA Assay
University of California, Irvine, Taiho Pharmaceutical Co., Ltd., Natera, Inc.
Colon Adenocarcinoma, Colorectal Cancer
12/24
12/25
NCT05296005: Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Not yet recruiting
1
20
US
Capecitabine, Ro 09-1978/000, Xeloda, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Surgical Procedure, Operation, Surgery, Surgery Type, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Ohio State University Comprehensive Cancer Center
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
12/23
12/24
NCT04357587: Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

Completed
1
6
US
Pembrolizumab, External beam radiation, Capecitabine
Case Comprehensive Cancer Center
Rectal Neoplasms
09/23
09/23
NCT04509596: DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Active, not recruiting
1
23
US, RoW
DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C
Dizal Pharmaceuticals
Breast Cancer Metastatic
01/24
05/24
PCS6422-GI-01, NCT04861987: A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Completed
1
23
US
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer, Refractory Cancer, Tumor Gastric
06/24
09/24
GASTO-10102, NCT06020885: Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Recruiting
1
18
RoW
Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy
Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
01/24
07/24
NCT05344742: A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Not yet recruiting
1
116
NA
Mitoxantrone Hydrochloride Liposome injection, Capecitabine, Albumin-paclitaxel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
03/24
03/25
NCT06300489: Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Recruiting
1
30
RoW
irinotecan liposomes+capecitabine, chemoradiotherapy
Zhejiang Cancer Hospital
Rectal Cancer
01/25
10/25
NCT05700084: Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors

Recruiting
1
84
RoW
Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A), Capecitabine, Utidelone Capsule (Part 3)
Beijing Biostar Pharmaceuticals Co., Ltd.
Advanced Solid Tumor
03/25
04/25
NCT06344156: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

Recruiting
1
43
RoW
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Sichuan University
Pancreatic Cancer, Adjuvant Therapy
04/26
04/27
NCT06409390: Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting
1
15
US
Taxotere, Docetaxel, Cytoxan, Cyclophosphamide, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy, Xeloda, Capecitabine, Fulvestrant, Faslodex, Ribociclib, Kisqali, Abemaciclib, Verzenio
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer
04/27
04/27
AdvanTIG-105, NCT04047862: Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors

Checkmark Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Completed
1
449
NA
Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
BeiGene
Locally Advanced and Metastatic Solid Tumors
08/24
08/24
NCT06406816: Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

Not yet recruiting
1
10
NA
Neoantigen Vaccine plus Capecitabine
Yongyi Zeng
Intrahepatic Cholangiocarcinoma
05/26
05/26
NCT06346808: Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

Not yet recruiting
1
20
RoW
Oncolytic virus Plus Anti-PD1 and Chemotherapy
Sichuan University
Pancreatic Cancer
05/26
05/27
SHR-A1904-301, NCT06350006: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Recruiting
1
924
RoW
SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Cldn18.2-positive Advanced Solid Tumor
12/27
12/28
ELVN-002-003, NCT06328738: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
255
US
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
ZWI-ZW25-101, NCT02892123: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Active, not recruiting
1
279
Canada, US, RoW
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Jazz Pharmaceuticals
HER2-expressing Cancers
10/24
10/24
NCT05320874: A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Not yet recruiting
1
232
RoW
KM257 Bispecific antibody
Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumor
06/24
11/26
NCT02199236: Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

Active, not recruiting
1
15
US
endorectal brachytherapy, concurrent capecitabine or 5-FU, Questionnaires, Bowel Function Assessment, Quality of Life Assessment
Memorial Sloan Kettering Cancer Center
Rectal or Anal Cancer
07/25
07/25
NL79619.078.21, NCT05379790: Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Recruiting
1
20
Europe
Irinotecan, Intraperitoneal irinotecan, CAPOX
Erasmus Medical Center
Gastric Cancer, Peritoneal Metastases
08/24
08/24
NCT05249426: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruiting
1
48
Europe, Japan, US, RoW
BI 765063, Ezabenlimab, BI 754091, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/24
08/25
NCT05704985: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Recruiting
1
60
US
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Pembrolizumab, Nivolumab, Chemotherapy, Paclitaxel, Carboplatin, Oxaliplatin, Fluorouracil, Capecitabine
DEKA Biosciences
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
09/24
02/25
NCT01061515: Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Active, not recruiting
1
21
US
Intraperitoneal Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda
Washington University School of Medicine
Carcinoma
09/24
09/24
NCT04664829: The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Recruiting
1
12
RoW
Bexarotene, Targretin, Capecitabine, Xeloda
National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore
Metastatic Triple-Negative Breast Carcinoma
09/24
09/25
NCT06610799: Study of IBI363 in Patients With Advanced First-line Gastric Cancer

Not yet recruiting
1
40
RoW
IBI363
Xiangdong Cheng
IBI363 + Chemotherapy
06/25
12/26
GO30103, NCT02794571: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Active, not recruiting
1
518
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A, RO5541267, Tecentriq, Tiragolumab, MTIG7192A, RO7092284, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Genentech, Inc.
Advanced/Metastatic Tumors
10/24
10/24
NCT05108428: Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Active, not recruiting
1
20
US
Capecitabine, Xeloda, Radiation Therapy, FOLFOX regimen
H. Lee Moffitt Cancer Center and Research Institute, Viewray Inc., Natera, Inc.
Rectal Adenocarcinoma
10/23
10/26
TUTOR, NCT05553522: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Recruiting
1
40
US
Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Baptist Health South Florida, Seagen Inc.
Brain Metastases, HER2-positive Breast Cancer
11/24
11/25
FORTRESS, NCT06459869: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Not yet recruiting
1
30
NA
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Akamis Bio
Locally Advanced Rectal Cancer (LARC)
02/26
01/29
NCT03153280: Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer

Active, not recruiting
1
2
Europe
Lithium, Oxaliplatin, Capecitabine
Cancer Trials Ireland, University College Cork
Colorectal Neoplasms, Stomach Neoplasm, Esophageal Neoplasms
12/24
12/26
NCT05417386: FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated
1
4
US
FOLFIRINOX, Oxaliplatin, Eloxatin, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, Irinotecan, Camptosar, Camptothecin-11, CPT-1, 5-Fluorouracil (5-FU), Adrucil, NIS793, Chemoradiation, Capecitabine, Xeloda, Radiation Therapy, Surgery
Colin D. Weekes, M.D., PhD, Novartis
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
07/23
07/23
NCT05064085: Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Active, not recruiting
1
13
US
Cemiplimab, Libtayo, Capecitabine, Xeloda
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals
Hormone Receptor-positive Breast Cancer
09/24
09/25
NCI-2015-00693, NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies

Terminated
1
221
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Eribulin, ER-086526, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Topotecan, Hycamptamine, Topotecan Lactone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC V8, Stage III Renal Cell Cancer AJCC V8, Stage IIIA Lung Cancer AJCC V8, Stage IIIB Lung Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
09/24
09/24
NORMANDY, NCT04696757: Non-OpeRative MANagement of Rectal Cancer Patients

Recruiting
1
15
RoW
Capecitabine
Kangbuk Samsung Hospital
Rectal Cancer, Chemoradiotherapy, Watch & Wait
12/24
12/24
AK104-PAN, ChiCTR2300077949: Efficacy and safety of AK104 combined chemotherapy for conversion therapy of advanced gastric/gastroesophageal junction adenocarcinoma with No. 16a2/b1 lymph node metastasis ----- multicenter, open, single-arm study

Recruiting
1
15
 
AK104 (cardonilizumab), 10mg/kg intravenously, day 1, every 3 weeks, Q3W; Oxaliplatin: 130 mg/m^2, IV, day 1, Q3W; Capecitabine: 1000mg/m^2 orally, twice daily, day 1 to day 14, Q3W.
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Akeso Pharma Co., Ltd
gastric adenocarcinoma
 
 
NCT06065371: Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Not yet recruiting
1
20
NA
Capecitabine, Xeloda, Sacituzumab govetican, Trodelvy
Henry Ford Health System, Gilead Sciences
Gastrointestinal Cancer
12/25
05/26
NCT04808323: MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Recruiting
1
22
US
Capecitabine, Xeloda, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX, Oxaliplatin de Gramont, OxMdG
Medical College of Wisconsin
Rectal Adenocarcinoma
06/25
06/26
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
ChiCTR2400088245: Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Recruiting
1
48
 
Mitoxantrone hydrochloride liposome + capecitabine
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd
HER-2 negative breast cancer
 
 
ACO/ARO/AIO-21, NCT04942626: Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients

Active, not recruiting
1
12
Europe
Kineret 100 MG in 0.67 ML Prefilled Syringe, Capecitabine, Radiotherapy, Watch and Wait (cCR) or TME surgery (non-cCR), W&W or TME
Goethe University
Rectal Cancer
12/24
12/25
SMART TNT, NCT05412082: for the Conservative Management of Locally Advanced Rectal Cancer

Recruiting
1
25
US
Intensity-modulated radiation therapy, IMRT, 5-fluorouracil, 5-FU, Leucovorin, Folinic acid, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Accelerated Radiation Therapy, ART
University of Miami
Locally Advanced Rectal Cancer
10/25
10/27
NCT04703101: Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Recruiting
1
25
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment, Surveillance, Epidemiology / Surveillance, Total Mesorectal Excision, TME
Jonsson Comprehensive Cancer Center, The Joseph Drown Foundation, Natera, Inc.
Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
10/25
10/26
NCT04615013: NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Recruiting
1
24
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Thoracic Esophagus Adenocarcinoma
10/25
10/25
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
120
Europe, Japan, US, RoW
RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Genentech, Inc., Chugai Pharmaceutical Co.
Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
12/25
12/25
ChiCTR2400079899: A randomized, open, parallel-controlled, multi-center phase III clinical study of HR070803 combined with oxaliplatin, 5-fluorouracil, and leucovorin versus gemcitabine combined with capecitabine for postoperative adjuvant treatment of pancreatic cancer.

Recruiting
1
524
 
HR070803+Oxaliplantin+5-FU/LV; Gemcitabine+Capecitabine
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, self-funded
pancreatic cancer
 
 
NCT05625412: A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Recruiting
1
220
Europe, Canada, US, RoW
BMS-986360, CC-90001, Docetaxel, Taxotere®, Nivolumab, Opdivo®, BMS-936558, Capecitabine, Xeloda®
Bristol-Myers Squibb
Advanced Solid Tumors
05/26
07/27
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
NCT05803382: Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Recruiting
1
30
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
06/26
06/26
ChiCTR2400085713: Clinical safety and efficacy of metronidazole combined with capecitabine/oxaliplatin in patients with inoperable pMMR/MSS Stage IV colorectal cancer

Not yet recruiting
1
9
 
Metronidazole 0.2g Tid; Metronidazole 0.4g Tid; Metronidazole 0.4g Bid
Beijing Hospital; Beijing Hospital, Optional project
pMMR/MSS colorectal cance
 
 
ChiCTR2300075094: PD-1 inhibitor and nimotuzumab plus induction chemotherapy, concurrent therapy, in combination with capecitabine as adjuvant therapy, for T3-4N3M0 nasopharyngeal carcinoma: a single arm, phase II clinical trial

Recruiting
1
29
 
Stage of induction traetment: 3 cycles of PD-1 inhibitor (200mg，d0，q3w) plus nimotuzumab (100mg，d0、d8，q3w) and chemotherapy (gemcitabine, 1000 mg/m2，d1、d8; cisplatin, 80mg/m2， d1，q3w), 21 days is a cycle. Stage of Concurrent treatment: cisplatin, 80mg/m2，d1，q3w, 2cycles; nimotuzumab 200mg，d1，qw; radiotherapy for nasopharynx and cervical metastatic lymph node. Stage of adjuvant treatment: Capecitabine (650mg/m2, take orally, two times every day) until 1 year or the end of the study.
The Tenth Affiliated Hospital of Southern Medical University (Dongguan people's hospital); The Tenth Affiliated Hospital of Southern Medical University (Dongguan people's hospital), Biotech Pharmaceutical Co., Ltd
nasopharyngeal carcinoma
 
 
NCT04523818: Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

Active, not recruiting
1
25
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Surgical Procedure
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
12/28
12/28
ChiCTR2100049018: A randomized, open-label, multicenter study to evaluate the efficacy and safety of continuation of original targeted therapy versus Trastuzumab combined with Pyrotinib and capecitabine as postoperative adjuvant therapy in patients with HER2-positive early breast cancer who have residual tumor present pathologically following

Recruiting
1
206
 
Trastuzumab + pyrotinib + capecitabine ;Continuation of original neoadjuvant therapy
Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Breast cancer
 
 
PRAAR1, NCT05912075: Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Recruiting
1
78
Europe
mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine, TOLINAPANT (ASTX660), Pelvic radiotherapy SCRT, FOLFOX4, CAPOX, Capecitabine + Oxaliplatine
Gustave Roussy, Cancer Campus, Grand Paris
Locally-advanced Rectal Cancer
01/28
01/29
NCT04627246: Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Recruiting
1
12
Europe
Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)
Centre Hospitalier Universitaire Vaudois
Pancreatic Adenocarcinoma
09/28
09/28

Download Options